Palvella CEO to Present at Two Key Healthcare Investor Conferences
Event summary
- Palvella CEO Wes Kaupinen to participate in Cantor Global Healthcare Conference on September 9, 2026.
- Kaupinen to present at H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026.
- Live webcasts and archived replays available on Palvella's website for 90 days post-event.
- Palvella focuses on rare skin diseases and vascular malformations with no FDA-approved therapies.
- Lead product candidate QTORIN™ rapamycin in development for microcystic lymphatic malformations and other conditions.
The big picture
Palvella's participation in these investor conferences underscores its push to highlight its pipeline of novel therapies for rare skin diseases and vascular malformations. The company's focus on conditions with no FDA-approved treatments positions it in a niche but growing segment of the biopharmaceutical market. Success will hinge on regulatory approvals and the ability to differentiate its QTORIN™ platform in a competitive landscape.
What we're watching
- Regulatory Progress
- How the FDA review process for QTORIN™ rapamycin will impact potential approval timelines.
- Market Positioning
- Whether Palvella can sustain momentum in the competitive rare disease treatment space.
- Financial Strategy
- The pace at which Palvella can secure additional funding to support clinical development.
Related topics